Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAge Labs (BIOA) Non-Current Debt (2023 - 2025)

BioAge Labs' Non-Current Debt history spans 3 years, with the latest figure at $1.1 million for Q1 2025.

  • On a quarterly basis, Non-Current Debt changed N/A to $1.1 million in Q1 2025 year-over-year; TTM through Mar 2025 was $1.1 million, a N/A change, with the full-year FY2024 number at $2.5 million, down 69.49% from a year prior.
  • Non-Current Debt hit $1.1 million in Q1 2025 for BioAge Labs, down from $2.5 million in the prior quarter.
  • Over the last five years, Non-Current Debt for BIOA hit a ceiling of $8.2 million in Q4 2023 and a floor of $1.1 million in Q1 2025.
  • Historically, Non-Current Debt has averaged $3.9 million across 3 years, with a median of $3.2 million in 2024.
  • The widest YoY moves for Non-Current Debt: up 69.49% in 2024, down 69.49% in 2024.
  • Tracing BIOA's Non-Current Debt over 3 years: stood at $8.2 million in 2023, then crashed by 69.49% to $2.5 million in 2024, then plummeted by 57.79% to $1.1 million in 2025.
  • Business Quant data shows Non-Current Debt for BIOA at $1.1 million in Q1 2025, $2.5 million in Q4 2024, and $3.9 million in Q3 2024.